Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 29;7(5):2042–2050. doi: 10.1002/ehf2.12834

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

GP approach (n = 500) after normalization of hyperkalaemia in patients under ACEi/ARBs (in the absence of details regarding medical history) and patients under MRA and history of HF and CKD. *Refer to open‐ended question 2.6: After resolution of hyperkalaemia, what is your approach toward these drugs (ACEi/ARBs)? (several answers were possible). **Refer to open‐ended question 2.4: After resolution of hyperkalaemia, what is your approach toward these drugs (Aldactone©, spironolactone; or Inspra©, eplerenone)? (several answers were possible). Legend: HF, heart failure; CKD, chronic kidney disease; ACEi, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; SPS, sodium polystyrene sulfonate; GP, general practitioner; MRA, mineralocorticoid receptor antagonist.